SEC Form 4	
------------	--

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Nu

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] EISENBERG GLENN A			2. Issuer Name and Ticker or Trading Symbol <u>LABORATORY CORP OF AMERICA</u> <u>HOLDINGS</u> [LH]		tionship of Reporting Per all applicable) Director Officer (give title	rson(s) to Issuer 10% Owner Other (specify			
(Last) 531 SOUTH SPR	(First) RING STREET	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/21/2024		below) Chief Financial C	below) fficer, EVP			
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicab Line)					
(Street)	NG	07015		X	Form filed by One Rep	oorting Person			
BURLINGTON	NC	27215			Form filed by More that Person	in One Reporting			
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication						
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(insu: 4)		
Common Stock	02/21/2024		М		14,054	A	\$163.63	58,099	D			
Common Stock	02/21/2024		S		18,379	D	\$215.3661(1)	39,720	D			
Common Stock	02/21/2024		S		7,907	D	\$215.6759 ⁽²⁾	31,813	D			
Common Stock	02/21/2024		S		6,665	D	\$217.5205(3)	25,148	D			
Common Stock	02/21/2024		S		1,553	D	\$ 217.9842 ⁽⁴⁾	23,595	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(9	., թ	-,	, .		, •p• , •							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Deri Sec Acq or D of (I	umber of ivative urities uired (A) Disposed D) (Instr. 3, id 5)	Expiration Date (Month/Day/Year)		of Securities Underlying		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Non- qualified Stock Options ⁽⁵⁾	\$163.63 ⁽⁶⁾	02/21/2024		М			14,054 ⁽⁶⁾	02/04/2021 ⁽⁷⁾	02/03/2030	Common Stock	14,054	\$0	0	D	

Explanation of Responses:

1. The price of \$215.3661 per share represents a weighted average of sales prices ranging from \$214.80 to \$215.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

2. The price of \$215.6759 per share represents a weighted average of sales prices ranging from \$215.80 to \$216.66 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

3. The price of \$217.5205 per share represents a weighted average of sales prices ranging from \$216.87 to \$217.86 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

4. The price of \$217.9842 per share represents a weighted average of sales prices ranging from \$217.89 to \$218.075 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

5. Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

6. Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea

7. The option vested in three equal annual installments beginning on the date reflected in this column.

/s/ Sandra D. van der Vaart,

Attorney-in-Fact for Glenn A.

Eisenberg

* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

02/22/2024